Literature DB >> 1371129

Antibody against the Leu-CAM beta-chain (CD18) promotes both LFA-1- and CR3-dependent adhesion events.

M K Robinson1, D Andrew, H Rosen, D Brown, S Ortlepp, P Stephens, E C Butcher.   

Abstract

The Leukocytic cell-adhesion molecule (beta 2 integrin) family of adhesion molecules play a key role in the intercellular adhesive interactions necessary for normal immune cell function. In this study, we report an antibody that recognizes an epitope on the Leukocytic cell-adhesion molecule common beta-chain (CD18) and promotes both lymphocyte function-associated Ag-1- and CR3-dependent adhesion events. The antibody recognizes a temperature-sensitive epitope that is not dependent on the presence of divalent cations. It is proposed that antibody binding promotes a conformational change in both lymphocyte function-associated Ag-1 and CR3, which may mimic a natural activation mechanism, resulting in increased cellular adhesion.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1371129

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


  72 in total

1.  Effects of I domain deletion on the function of the beta2 integrin lymphocyte function-associated antigen-1.

Authors:  B Leitinger; N Hogg
Journal:  Mol Biol Cell       Date:  2000-02       Impact factor: 4.138

2.  Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains.

Authors:  C Lu; M Shimaoka; Q Zang; J Takagi; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  Definition of EGF-like, closely interacting modules that bear activation epitopes in integrin beta subunits.

Authors:  J Takagi; N Beglova; P Yalamanchili; S C Blacklow; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

4.  Activation of integrin beta-subunit I-like domains by one-turn C-terminal alpha-helix deletions.

Authors:  Wei Yang; Motomu Shimaoka; JianFeng Chen; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

5.  Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring.

Authors:  Wei Yang; Motomu Shimaoka; Azucena Salas; Junichi Takagi; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

6.  SRC-dependent outside-in signalling is a key step in the process of autoregulation of beta2 integrins in polymorphonuclear cells.

Authors:  Paola Piccardoni; Stefano Manarini; Lorenzo Federico; Zsuzsa Bagoly; Romina Pecce; Nicola Martelli; Antonio Piccoli; Licia Totani; Chiara Cerletti; Virgilio Evangelista
Journal:  Biochem J       Date:  2004-05-15       Impact factor: 3.857

7.  The C-terminal αI domain linker as a critical structural element in the conformational activation of αI integrins.

Authors:  Gabriele Weitz-Schmidt; Thomas Schürpf; Timothy A Springer
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

8.  Requirement of open headpiece conformation for activation of leukocyte integrin alphaXbeta2.

Authors:  Xing Chen; Can Xie; Noritaka Nishida; Zongli Li; Thomas Walz; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

9.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

10.  The integrin alpha-subunit leg extends at a Ca2+-dependent epitope in the thigh/genu interface upon activation.

Authors:  Can Xie; Motomu Shimaoka; Tsan Xiao; Pascale Schwab; Lloyd B Klickstein; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-19       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.